Skip to main content

Advertisement

Fig. 2 | Journal of Nanobiotechnology

Fig. 2

From: In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosis

Fig. 2

Human conjunctival fibroblasts were treated with different concentrations of nanocarrier CCG-222740 or empty liposomes for 24 h. a ACTA2 gene expression was measured by real-time quantitative PCR. Results represent mean ± SEM for triplicate experiments. *P < 0.05. Comparisons shown are between cells treated with different concentrations of nanocarrier CCG-222740 or empty liposomes. b Effect on cell viability was measured using CellTiter 96 Aqueous one solution assay. Results represent mean ± SEM for six replicates per condition. The comparisons of cell viabilities shown are between cells treated with different concentrations of nanocarrier CCG-222740 or empty liposomes

Back to article page